Soluble Fas: a useful marker of inflammation and cardiovascular diseases in uremic patients

Background Inflammation has been associated with atherosclerotic cardiovascular disease (CVD) and anemia in patients with end-stage renal disease (ESRD) which may lead to left ventricular impairment via myocardial hypertrophy and/or ischemia. We therefore sought to investigate serum levels of sFas in uremic patients and its correlation with known markers of inflammation and CVD.